Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pharmacogenomics Testing Clear all
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)

NCT05966129
View directory record Official record
Conditions
Acute Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
8 Years and older
Enrollment
1,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 16, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

NCT03729180
View directory record Official record
Conditions
Surgery
Interventions
Routine Elective Surgery- In patient or out patient elective surgery, Blood test for genetic testing, Drug-genetic Profile
Procedure · Diagnostic Test · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 16, 2026, 4:02 AM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 16, 2026, 4:02 AM EDT
Not listed Not applicable Interventional

Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care

NCT04685304
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic Testing, Pharmacist Consultation Note, Delayed pharmacogenetic testing
Genetic · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

NCT03023891
View directory record Official record
Conditions
Glucocorticoids Toxicity, Glucose Intolerance
Interventions
Prednisone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 16, 2026, 4:02 AM EDT
Completed No phase listed Observational

Genetic Evaluation for Medication Selection (GEMS) Study

NCT03736057
View directory record Official record
Conditions
Dementia, Psychiatric Disorders Mood, Behavior Disorders
Interventions
Delayed results of pharmacogenomic results
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
40 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

NCT00025363
View directory record Official record
Conditions
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
vincristine sulfate, irinotecan hydrochloride, cyclophosphamide, doxorubicin hydrochloride, ifosfamide, etoposide, tirapazamine, filgrastim, sargramostim, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 16, 2026, 4:02 AM EDT
Completed No phase listed Observational

Pharmacologic Impact on Sedation Assessments

NCT01105663
View directory record Official record
Conditions
Pediatric Acute Lung Injury
Interventions
Pharmacokinetic Sampling and pharmacogenetic analysis
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 16, 2026, 4:02 AM EDT
Terminated Phase 1 Interventional Results available

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

NCT01705106
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, celecoxib, pharmacological study, laboratory biomarker analysis, pharmacogenomic studies
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00735917
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
saracatinib, pharmacogenomic studies, pharmacological study, positron emission tomography, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

NCT01334177
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis, pharmacogenomic studies
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 16, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

NCT05656469
View directory record Official record
Conditions
Mood Disorders, Anxiety Disorders, Psychotic Disorders
Interventions
Personalised medication advice based on pharmacogenetic testing
Other
Lead sponsor
Parnassia Groep
Other
Eligibility
16 Years to 70 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 16, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients

NCT02542397
View directory record Official record
Conditions
Malignant Tumor of Ill-defined Site
Interventions
Pharmacogenomic Testing
Genetic
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 16, 2026, 4:02 AM EDT
Withdrawn Not applicable Interventional

Prospective Study to Evaluate the Clinical Utility of Perioperative Pharmacogenomic Testing

NCT03531268
View directory record Official record
Conditions
Perioperative/Postoperative Complications
Interventions
PGx Testing
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Results available

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

NCT00991081
View directory record Official record
Conditions
Smoking
Interventions
Counseling, Self-help guide, Pharmacotherapy, Genetic feedback, verbal, Genetic feedback, printed
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Menlo Park, California • Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 16, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional

Informing Pain Treatment Using Pharmacogenomic Analysis

NCT06511401
View directory record Official record
Conditions
Adult Patients Who Are Receiving Oncologic Care
Interventions
Pharmacogenomic (PGx) results.
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 16, 2026, 4:02 AM EDT
Terminated Not applicable Interventional

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

NCT03455751
View directory record Official record
Conditions
Colorectal Cancer, Diverticular Disease, Crohn Disease, Ulcerative Colitis
Interventions
PGx-guided post-operative pain management
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

Pharmacogenomic Testing to Personalize Supportive Oncology

NCT04500301
View directory record Official record
Conditions
Cancer, Depression, Pain
Interventions
Preemptive Pharmacogenomic Testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 16, 2026, 4:02 AM EDT
Active, not recruiting Not applicable Interventional

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

NCT06660264
View directory record Official record
Conditions
Pharmacogenetics, Pharmacogenomic Drug Interaction
Interventions
Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 16, 2026, 4:02 AM EDT
Active, not recruiting Not applicable Interventional

Effectiveness of PGx Testing

NCT04120480
View directory record Official record
Conditions
Polypharmacy
Interventions
Pharmacogenomic test
Diagnostic Test
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 79 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 16, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)

NCT05966142
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 16, 2026, 4:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetic Testing in Primary Care

NCT01600846
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 16, 2026, 4:02 AM EDT